May 12, 2017 10:57 AM EDT

Alnylam adds a slate of new executives; Thomas Insel is leaving Verily; Akari CEO Gur Roshwalb placed on leave

ENDPOINTS

→ Scott Gottlieb was sworn in as America’s 23rd Commissioner of Food and Drugs yesterday.

Honored to swear in Dr. Scott Gottlieb as the @US_FDA Commissioner this morning. We are excited to have him join the @HHSGov family! pic.twitter.com/ABl838QiIF

— Tom Price, M.D. (@SecPriceMD) May 11, 2017

→ RNAi biotech Alnylam named a

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Alnylam adds a slate of new executives; Thomas Insel is leaving Verily; Akari CEO Gur Roshwalb placed on leave

ENDPOINTS

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Compounded weight loss drugs have resulted in misdosing, hospitalizations, FDA warns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Al­ny­lam adds a slate of new ex­ec­u­tives; Thomas In­sel is leav­ing Ver­i­ly; Akari CEO Gur Rosh­walb placed on leave

ENDPOINTS

Sign up to read this article for free.

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Com­pound­ed weight loss drugs have re­sult­ed in mis­dos­ing, hos­pi­tal­iza­tions, FDA warns

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

Alnylam adds a slate of new executives; Thomas Insel is leaving Verily; Akari CEO Gur Roshwalb placed on leave

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Compounded weight loss drugs have resulted in misdosing, hospitalizations, FDA warns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?